KRAS: Druggable at Last

The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.

Detalles Bibliográficos
Autores principales: Herzberg, Benjamin O, Manji, Gulam A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078900/
https://www.ncbi.nlm.nih.gov/pubmed/36933199
http://dx.doi.org/10.1093/oncolo/oyad014
_version_ 1785020615831322624
author Herzberg, Benjamin O
Manji, Gulam A
author_facet Herzberg, Benjamin O
Manji, Gulam A
author_sort Herzberg, Benjamin O
collection PubMed
description The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.
format Online
Article
Text
id pubmed-10078900
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100789002023-04-07 KRAS: Druggable at Last Herzberg, Benjamin O Manji, Gulam A Oncologist Commentaries The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better. Oxford University Press 2023-03-18 /pmc/articles/PMC10078900/ /pubmed/36933199 http://dx.doi.org/10.1093/oncolo/oyad014 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentaries
Herzberg, Benjamin O
Manji, Gulam A
KRAS: Druggable at Last
title KRAS: Druggable at Last
title_full KRAS: Druggable at Last
title_fullStr KRAS: Druggable at Last
title_full_unstemmed KRAS: Druggable at Last
title_short KRAS: Druggable at Last
title_sort kras: druggable at last
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078900/
https://www.ncbi.nlm.nih.gov/pubmed/36933199
http://dx.doi.org/10.1093/oncolo/oyad014
work_keys_str_mv AT herzbergbenjamino krasdruggableatlast
AT manjigulama krasdruggableatlast

Ejemplares similares